Quince Therapeutics Inc
QNCX
Company Profile
Business description
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Contact
611 Gateway Boulevard
Suite 273
South San FranciscoCA94080
USAT: +1 415 910-5717
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
Overpriced ASX listed consumer electronics retailers
Solid balance sheets, lower business risk and strong sales but investors are overly optimistic.
stocks
Nvidia and AMD: Maintain fair value estimate amid reports of Meta’s negotiations to buy Google TPUs
Our update on select stocks from the Semiconductors industry.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,907.90 | 17.00 | 0.19% |
| CAC 40 | 8,099.47 | 3.04 | 0.04% |
| DAX 40 | 23,767.96 | 41.74 | 0.18% |
| Dow JONES (US) | 47,427.12 | 1,181.71 | 2.56% |
| FTSE 100 | 9,693.93 | 2.35 | 0.02% |
| HKSE | 25,945.93 | 17.85 | 0.07% |
| NASDAQ | 23,214.69 | 189.10 | 0.82% |
| Nikkei 225 | 50,167.10 | 608.03 | 1.23% |
| NZX 50 Index | 13,445.91 | 13.71 | 0.10% |
| S&P 500 | 6,812.61 | 46.73 | 0.69% |
| S&P/ASX 200 | 8,608.10 | 16.30 | 0.19% |
| SSE Composite Index | 3,875.26 | 11.08 | 0.29% |